UBS Group AG Has $9.38 Million Position in Cogent Biosciences, Inc. $COGT

UBS Group AG lowered its position in Cogent Biosciences, Inc. (NASDAQ:COGT) by 85.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 264,047 shares of the technology company’s stock after selling 1,589,625 shares during the quarter. UBS Group AG owned 0.19% of Cogent Biosciences worth $9,379,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Cogent Biosciences by 48.4% in the fourth quarter. Vanguard Group Inc. now owns 11,514,326 shares of the technology company’s stock valued at $408,989,000 after buying an additional 3,756,664 shares during the period. Deerfield Management Company L.P. boosted its holdings in Cogent Biosciences by 242.9% in the third quarter. Deerfield Management Company L.P. now owns 9,053,118 shares of the technology company’s stock valued at $130,003,000 after acquiring an additional 6,412,903 shares during the last quarter. Fairmount Funds Management LLC boosted its holdings in Cogent Biosciences by 44.6% in the third quarter. Fairmount Funds Management LLC now owns 9,003,418 shares of the technology company’s stock valued at $129,289,000 after acquiring an additional 2,777,777 shares during the last quarter. Commodore Capital LP boosted its holdings in Cogent Biosciences by 213.7% in the third quarter. Commodore Capital LP now owns 7,250,000 shares of the technology company’s stock valued at $104,110,000 after acquiring an additional 4,938,836 shares during the last quarter. Finally, Vestal Point Capital LP boosted its holdings in Cogent Biosciences by 2.7% in the second quarter. Vestal Point Capital LP now owns 3,080,000 shares of the technology company’s stock valued at $22,114,000 after acquiring an additional 80,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, April 10th. Wall Street Zen cut Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Jefferies Financial Group assumed coverage on Cogent Biosciences in a report on Monday, March 16th. They issued a “buy” rating and a $55.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $55.00 target price on shares of Cogent Biosciences in a report on Tuesday, March 17th. Finally, Piper Sandler upped their target price on Cogent Biosciences from $39.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.73.

Cogent Biosciences Price Performance

Shares of COGT opened at $32.68 on Friday. Cogent Biosciences, Inc. has a 12-month low of $4.55 and a 12-month high of $43.73. The business’s fifty day moving average is $35.82 and its 200 day moving average is $35.46. The company has a quick ratio of 15.14, a current ratio of 15.14 and a debt-to-equity ratio of 0.41. The stock has a market cap of $5.58 billion, a P/E ratio of -15.06 and a beta of 0.37.

Cogent Biosciences (NASDAQ:COGT) last issued its earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.53). Sell-side analysts anticipate that Cogent Biosciences, Inc. will post -2.23 earnings per share for the current fiscal year.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.